Baxter(US:BAX) Prnewswireยท2025-11-21 15:20Core Viewpoint - Baxter International Inc. is facing a federal securities class action lawsuit due to allegations of making false and misleading statements regarding the safety and efficacy of its Novum LVP product, which has been linked to serious malfunctions and patient risks [3][4]. Summary by Sections Legal Investigation - Faruqi & Faruqi, LLP is investigating potential claims against Baxter International and has set a deadline of December 15, 2025, for investors to seek the role of lead plaintiff in the class action [1][5]. Allegations Against Baxter - The complaint alleges that Baxter and its executives violated federal securities laws by failing to disclose systemic defects in the Novum LVP, which led to malfunctions such as underinfusion and overinfusion, posing risks of serious injury or death to patients [3]. - Baxter was reportedly aware of multiple device malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of customers removing the Novum LVPs from service [3]. Impact on Stock Price - Following the announcement on July 31, 2025, that Baxter would "voluntarily and temporarily pause shipments and planned installations" of the Novum LVP, the company's stock price fell by 22.4%, closing at $21.76 [4].